Welcome to our dedicated page for Exponent SEC filings (Ticker: EXPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The EXPO SEC filings page on Stock Titan provides access to Exponent, Inc.’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed science and engineering consulting firm, Exponent uses SEC reports to present detailed information about its financial condition, operating performance, and material events. These filings complement the company’s earnings releases and offer structured data on revenues before reimbursements, operating expenses, segment performance, and non-GAAP measures such as EBITDA and EBITDAS.
Investors can use this page to locate Exponent’s periodic reports, including annual and quarterly filings that discuss its two operating segments: the engineering and other scientific segment and the environmental and health segment. These documents describe how much each segment contributes to revenues before reimbursements and provide narrative explanations of demand trends in areas such as dispute-related services, risk management projects, and regulatory consulting across industries like construction, automotive, medical devices, utilities, chemicals, transportation, and life sciences.
The EXPO filings page also highlights current reports on Form 8-K, where Exponent discloses material events. Recent 8-K filings have incorporated press releases announcing quarterly financial results, dividend declarations, and changes to share repurchase authorizations. These filings give timely insight into board decisions on capital returns and into management’s assessment of market conditions and business performance.
Stock Titan enhances access to these documents with AI-powered summaries that explain key sections in plain language, helping readers interpret complex accounting and technical terminology. Users can quickly see how Exponent’s reported metrics, segment data, and capital allocation actions fit into its broader consulting business. This makes the EXPO SEC filings page a useful starting point for understanding Exponent’s regulatory history and ongoing reporting as a professional, scientific, and technical services company.
Exponent, Inc. announced a series of leadership changes, highlighted by the appointment of John D. Pye, Ph.D. as President and Eric Anderson as Chief Financial Officer, both effective May 1, 2026. Pye, a long‑tenured engineering leader at the firm, will receive a base salary of $650,000 and stock options for 21,000 shares vesting over four years. Anderson, who has led finance and accounting, will receive a $525,000 base salary and options for 12,600 shares, also vesting over four years.
Current CFO and Executive Vice President Richard L. Schlenker will cease serving as CFO on May 1, 2026 but remain Executive Vice President and has been nominated to stand for election to the Board of Directors. Paul R. Johnston, Ph.D., current Chairman and former CEO, will retire from the Board at the Annual Meeting of Stockholders on June 4, 2026, when Karen Richardson, now Lead Independent Director, will become Chairman of the Board. The company emphasizes continuity, noting there are no related‑party arrangements or family relationships involving the newly appointed executives.
The Vanguard Group filed Amendment No. 15 to a Schedule 13G/A reporting 0 shares of Exponent Inc. common stock. The filing states Vanguard underwent an internal realignment on January 12, 2026 and certain subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538.
The amendment lists amount beneficially owned: 0 and percent of class: 0%, and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Catherine Corrigan filed a Form 144 reporting a proposed sale of 3,912 shares of Common Stock via the exercise of stock options on 03/16/2026 for cash. The broker listed is Morgan Stanley Smith Barney LLC.
Prior 10b5-1 sales shown in the excerpt include 3,920 shares sold on 02/17/2026 for $263,239.62 and 1,663 shares sold on 01/15/2026 for $120,593.78.
SCHLENKER RICHARD L JR reported acquisition or exercise transactions in this Form 4 filing.
Exponent Inc. reported that EVP & Chief Financial Officer Richard L. Schlenker Jr. received a grant of 10,688 restricted stock units on March 13, 2026. Each unit represents a right to receive one share of common stock on a 1-for-1 basis. Following this compensation-related award, he holds 10,688 restricted stock units directly.
Sala Joseph reported acquisition or exercise transactions in this Form 4 filing.
Exponent Inc reported that Group Vice President Joseph Sala received a grant of 9,798 Restricted Stock Units on March 13, 2026. These RSUs are a form of stock-based compensation, with each unit convertible into one share of Exponent common stock on a 1-for-1 basis.
Following this award, Sala holds 9,798 RSUs directly, all tied to Exponent common stock. The grant was made at no cash cost per unit and reflects routine executive equity compensation rather than an open-market stock purchase or sale.
Exponent Inc reported that Group Vice President Maureen T. F. Reitman received a grant of 9,500 restricted stock units (RSUs) on March 13, 2026. Each RSU represents a right to receive one share of Exponent common stock, giving her 9,500 RSUs outstanding after this award. These units vest into common shares based on the company’s terms, with an exercise and expiration date in March 2030, and were granted at no cash cost to her as part of equity compensation.
Reiss Richard reported acquisition or exercise transactions in this Form 4 filing.
Exponent Inc reported that Group Vice President Richard Reiss received a grant of 2,970 restricted stock units on March 13, 2026. These RSUs represent the right to receive 2,970 shares of common stock on a 1-for-1 basis, as noted in the footnotes. Following this award, his reported derivative holdings in these RSUs total 2,970 units, reflecting routine equity-based compensation rather than any open-market buying or selling of shares.
Exponent Inc reported that Group Vice President Joseph Rakow received a grant of 10,688 restricted stock units on March 13, 2026. These RSUs represent a right to receive an equal number of shares of Exponent common stock on a 1-for-1 basis and are shown at a price of $0.00 because they are an equity award, not a market purchase. Following this grant, Rakow holds 10,688 RSUs directly, with an exercise and expiration date of March 13, 2030.
Exponent Inc reported that VP Global Offices & Innovation John Pye received a grant of 5,938 restricted stock units (RSUs) on March 13, 2026. These RSUs are a compensation-related award with a stated price of $0.00 per unit and each unit is exchangeable on a 1-for-1 basis into shares of common stock.
Following this award, Pye holds 5,938 RSUs directly. The RSUs relate to an equal number of underlying shares of common stock and are scheduled with an exercise and expiration date of March 13, 2030, indicating a long-term equity incentive rather than an open-market purchase.
Kundert Brian reported acquisition or exercise transactions in this Form 4 filing.
Exponent Inc. reported that Chief Human Resources Officer Brian Kundert received a grant of 3,564 restricted stock units on March 13, 2026. These units represent a 1-for-1 right to receive shares of common stock, typically as part of long-term equity compensation.
Following this award, he is reported as holding 3,564 restricted stock units directly. The transaction is recorded as a grant or award, not an open-market purchase or sale, and therefore reflects standard executive compensation rather than a discretionary trade.